Merz Pharma Group granted early termination in connection with BioForm Medical share tender offer

Merz Pharma Group today announced that it has been granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, by the U.S. Federal Trade Commission and the U.S. Department of Justice in connection with the previously announced US$5.45 per share cash tender offer made by Merz GmbH & Co. KGaA (“Merz”) and its acquisition subsidiary to purchase all outstanding shares of common stock of BioForm Medical, Inc. (Nasdaq: BFRM). The tender offer will expire on February 12, 2010 at 12:00 midnight, New York City time, unless extended.

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.